26.90

9.85% -2.94

Pre-market: 26.70 -0.20 -0.74%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $26.90, with a volume of 2.53M. It is down -9.85% in the last 24 hours and up +10.79% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Previous Close:

$29.84

Open:

$30.221

24h Volume:

2.53M

Relative Volume:

1.02

Market Cap:

$4.29B

Revenue:

$295.41M

Net Income/Loss:

$-49.64M

P/E Ratio:

-82.16

EPS:

-0.3274

Net Cash Flow:

$-29.54M

1W Performance:

-6.50%

1M Performance:

+10.79%

6M Performance:

+91.05%

1Y Performance:

+85.90%

1-Day Range:

$26.85

$30.74

1-Week Range:

$26.85

$30.74

52-Week Range:

$12.00

$30.74

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1066)

Industry

Diagnostics & Research (50)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

624

Twitter

@adaptivebiotech

Next Earnings Date

2026-11-04

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT vs TMO, DHR, NTRA, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	26.90	4.70B	295.41M	-49.64M	-29.54M	-0.3274
TMO Thermo Fisher Scientific Inc	656.58	241.26B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	215.61	150.48B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	400.65	59.47B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	169.33	48.71B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	436.43	42.59B	3.77B	449.25M	240.68M	7.8556

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Oct 01, 2026

Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT). - Stock Titan

Oct 01, 2026

Adaptive Biotechnologies slips as recent rally cools despite no clear new negative catalyst - Quiver Quantitative

Oct 01, 2026

ADPT Maintained by Guggenheim -- Price Target Raised to $32 - GuruFocus

Oct 01, 2026

Sep 29, 2026

ETFs Investing in Adaptive Biotechnologies Corp. Stocks - TradingView

Sep 29, 2026

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rated "Buy" in New Coverage at The Goldman Sachs Group - MarketBeat

Sep 29, 2026

ADPT Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus

Sep 29, 2026

Sep 28, 2026